Loss of HER2 and Decreased T-DM1 Efficacy in HER2 Positive Advanced Breast Cancer Treated with Dual HER2 Blockade. the SePHER Study.
Bon Giulia,Pizzuti Laura,Laquintana Valentina,Loria Rossella,Porru Manuela, Candiolo Cancer Institute, FPO-IRCCS,Krasniqi Eriseld,Barba Maddalena,Maugeri-Saccà Marcello,Gamucci Teresa,Berardi Rossana,Livi Lorenzo,Ficorella Corrado,Natoli Clara,Cortesi Enrico,Generali Daniele,La Verde Nicla,Cassano Alessandra, University of Verona,Moscetti Luca,Michelotti Andrea,Adamo Vincenzo,Zamagni Claudio,Tonini Giuseppe,Barchiesi Giacomo,Mazzotta Marco, Sant’Andrea University Hospital,Tomao Silverio,Valerio Maria Rosaria,Mirabelli Rosanna,Russo Antonio,Fabbri Maria Agnese,D’Ostilio Nicola,Veltri Enzo,Corsi Domenico,Garrone Ornella,Paris Ida,Sarobba Giuseppina,Giotta Francesco,Garufi Carlo,Cazzaniga Marina,Del Medico Pietro,Roselli Mario,Sanguineti Giuseppe,Sperduti Isabella, IRCCS Foundation University A. Gemelli,Leonetti Carlo,Di Leo Angelo,Ciliberto Gennaro,Falcioni Rita,Vici Patrizia Journal of Experimental & Clinical Cancer Research（2020）
Key words
HER2+ breast cancer,Trastuzumab/pertuzumab blockade,T-DM1 efficacy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper